



(51) International Patent Classification:

C07D 213/74 (2006.01) *C07D 231/12* (2006.01)
C07D 239/42 (2006.01) *A61K 31/44* (2006.01)
C07D 249/06 (2006.01) *A61K 31/506* (2006.01)
C07D 271/07 (2006.01) *A61P 25/18* (2006.01)

(21) International Application Number:

PCT/GB2015/050480

(22) International Filing Date:

19 February 2015 (19.02.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

14156011.0 20 February 2014 (20.02.2014) EP

(71) Applicant (for MG only): **TAKEDA CAMBRIDGE LIMITED** [GB/GB]; 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0PA (GB).

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-Chome, Chou-Ku, Osaka-Shi, Osaka 541-0045 (JP).

(72) Inventors: **FIELDHOUSE, Charlotte**; c/o Takeda Cambridge Limited, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0PA (GB). **GLEN, Angela**; c/o Takeda Cambridge Limited, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0PA (GB). **MAINE, Stephanie**; c/o Takeda Cambridge Limited, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0PA (GB). **FUJIMOTO, Tatsuhiko**; c/o Takeda Pharmaceutical Company Limited, Shonan Research Center, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555 (JP). **ROBINSON, John Stephen**; c/o Takeda Cambridge

Limited, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0PA (GB).

(74) Agents: **JOHNSON, Stephen** et al.; Venner Shipley LLP, Byron House, Cambridge Business Park, Cowley Road, Cambridge Cambridgeshire CB4 0WZ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS



(57) Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L, X, R^a, R^b, R¹, R² and R³ are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.